Misfolding and aggregation of amyloid-b (Ab), tau, a-synuclein (a-syn), superoxide dismutase 1 (SOD1), and huntingtin exon 1 (HTTexon1) are tightly linked to Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), respectively (Goedert et al., 2010; Goedert, 2015) . The ability of these protein particles to transfer from one cell to another, similar to the aggregated form of the prion protein (PrP RES ; RES, resistant to proteolysis) in Creutzfeldt-Jakob disease (CJD), accounts for the widespread pathophysiology seen in neurodegenerative disorders. The cell-to-cell ''prion-like'' transfer of misfolded protein aggregates involves release from one neuron, uptake by nearby neurons, and, last, seeded assembly of misfolded host proteins in recipient neurons. Several excellent reviews cover the topic of cellto-cell transfer in detail (Brundin et al., 2010; Jucker and Walker, 2013) ; however, the pathophysiological effect of misfolded protein aggregates binding to the plasma membrane, including interaction with the biomolecules therein, in particular under non-acute experimental conditions, has not been specifically addressed. In this review, we discuss biophysical mechanisms that regulate the behavior of pathogenic assemblies following release from the donor neuron prior to their internalization within the recipient neurons. The review will focus on experimental evidence showing that pathogenic proteins bind to several biomolecules (proteins, lipids, and carbohydrates) at the plane of the plasma membrane. These stochastic interactions initiate multiple deleterious signaling pathways that can directly or indirectly trigger a cascade of events that ultimately lead to pathological symptoms. They also play a key role in pathogenic protein uptake, seeded aggregation of the endogenous proteins, and rapid proteostasis collapse. Thus, the interactions of pathogenic assemblies with membrane components very likely contribute to and add on cell autonomous factors that increase the vulnerability of healthy neurons (Saxena and Caroni, 2011; Surmeier et al., 2017) .
Structure of Pathogenic Protein Assemblies and Pathology
The constituents of pathogenic protein assemblies participate in many cellular processes. For instance, tau is involved in the stabilization of microtubules (Wang and Mandelkow, 2016) . Monomeric Ab peptides have neurotrophic and neuroprotective functions (Chasseigneaux and Allinquant, 2012) . Huntingtin is involved in scaffolding, transport, and autophagy processes (Saudou and Humbert, 2016) . a-Syn regulates synaptic transmission and calcium and mitochondrial homeostasis (Benskey et al., 2016) . The aggregation of these proteins into mega-Dalton assemblies results in the loss of their cellular functions and the acquisition of deleterious properties (Ross and Poirier, 2004; Tyedmers et al., 2010 . Although made of proteins with different primary structures, pathogenic protein assemblies share several common properties. First, they form a continuum of oligomeric species ranging from dimers to fibrillar assemblies . These fibrils could be straight, resembling needles, or, in other instances, be curved and twisted . Second, aggregated pathogenic assemblies propagate from cell to cell and amplify themselves by recruiting soluble/monomeric proteins (Brundin et al., 2010) . Third, pathogenic assemblies also share structural similarities within fibrils, where the constituting monomers are organized into parallel or anti-parallel, systematically hydrogen-bonded b sheets from which water molecules are excluded (Eisenberg and Jucker, 2012) . When uncharged, the side chains extending from one b sheet interdigitate, like the teeth of a zipper, with those extending from another b sheet. When charged, the side chains are exposed to the surface of the fibrillar core (Eisenberg and Jucker, 2012) . Thus, the side chains generate surfaces characteristic for each fibrillar assembly.
The fibrillar protein assemblies associated with AD, PD, ALS, HD, and CJD differ by their surfaces because of differences in their primary structures. Differences in the surface of fibrils also exist for pathogenic assemblies made of one given protein, and they are referred to as strains (Melki, 2015) . For a given pathogenic protein, different surface characteristics result from the conditions under which they formed. As a consequence, strains will have different biophysical properties and, likely, distinct interactomes. Interesting and in agreement with this view is the finding that fibrillar full-length and wild-type a-syn assemblies with distinct surfaces, although made of the same protein, yield different pathologies Peelaerts et al., 2015) . Similar strain-dependent pathologies for mostly truncated tau assemblies Sanders et al., 2014) and Ab assemblies (Stö hr et al., 2014) have been reported. Although the concept of strains is very new for a-syn, Ab, and tau, strain-dependent pathology has been long known and well documented for PrP RES (Collinge and Clarke, 2007) . Whether distinct surfaces of pathogenic protein assemblies and their location may account for the differences in their spatial and temporal route by which the pathology spreads within the brain remains an open question.
Pathogenic Protein Formation and Traffic
Ab is an extracellular cleavage product of amyloid precursor protein, whereas a-syn and tau, HTTexon1, and SOD1 are intracellular proteins. Because of the predominantly extra-cellular localization of Ab peptides, they can form aggregates, termed amyloid plaques, within the extracellular space when their local concentration exceeds the critical concentration for aggregate formation (Jucker and Walker, 2013) . The concentration of all the other polypeptides listed above is high within axons, and, expectedly, they form intracellular aggregates. Several studies have demonstrated that a-syn, tau, and HTTexon1 are secreted from cells, independent of cell death, both in non-toxic monomeric form and toxic fibrillar forms (Kfoury et al., 2012; Brahic et al., 2016; Wu et al., 2016; Ren et al., 2009; Hansen et al., 2011; Takeda et al., 2015; Wegmann et al., 2016) . The exact state of pathogenic assemblies outside of cells is still unclear, but both naked and membrane-encapsulated forms have been reported. This review neither covers the behavior of pathogenic assemblies within membranous compartments, because they may not directly interact with the plasma membrane components, nor the transfer of pathogenic assemblies via tunneling nanotubes, because this process bypasses the release and uptake pathways (Abounit et al., 2016; Tardivel et al., 2016) . In the following sections, we will focus on the biophysical properties of pathogenic proteins following their release from one cell and binding to the plasma membrane of neighboring cells.
3D-to-2D Environmental Transition of Pathogenic Proteins
In 1905, Albert Einstein predicted that the random motions of molecules in a liquid would affect suspended particles, resulting in irregular, random motions of the particles or Brownian diffusion (Einstein, 1905 ; Box 1). The mode of diffusion in a biological environment is referred to as anomalous diffusion, which means that the mean square displacement of a molecule does not follow a linear relationship with time and is governed by size distribution of surrounding molecules, molecular density, and inter-molecular interactions (Bouchaud and Georges, 1990; Dix and Verkman, 2008 ; see Box 1 for definitions, equations, and figure) . Protein mega-Dalton assemblies involved in diseases, such as Ab, a-syn, tau, etc., are heterogeneous in nature and behave in a complex manner after their release in the extracellular space, where they exhibit 3D diffusion. The corresponding diffusion coefficients are difficult to predict because this will depend on their size, concentration, molecular density of the extracellular space, and the presence of partner molecules with which they may interact. Misfolded protein assemblies, naked or in complex with other secreted proteins, have to cross the extracellular matrix (ECM) environment to reach the ''target'' plasma membrane, where they may interact with proteins, lipid molecules, and/or membrane-associated ECM components ( Figure 1 ). Then, after binding to the plasma membrane, the diffusion is restricted from 3D to a 2D diffusion in a crowded plane (see inset Figure B in Box 1). The reduced freedom of dimension available for diffusion increases the probability of molecular collisions with other proteins, including homologous ones, and then leads to the formation of clusters on the plasma membrane (Byströ m et al., 2008) . This dynamic phenomenon has been observed for Ab (Renner et al., 2010; Shrivastava et al., 2013; Ganzinger et al., 2014; Calamai et al., 2016 ) and a-syn (Shrivastava et al., 2015) assemblies. It is difficult to estimate the volume explored by a given pathogenic protein in vivo after it has been released in the extracellular space, which corresponds to 15%-20% of the normal adult brain volume (Syková and Nicholson, 2008) . When pathogenic protein assemblies are injected within a brain region, a 3D diffusion-dependent spread is seen around the injection site, and the spreading is proportional to the size of the protein assemblies (Rey et al., 2013; Selenica et al., 2013; Peelaerts et al., 2015; Shrivastava et al., 2015) . However, at early disease stages, the amount of released misfolded protein assemblies is likely to be small, and they propagate along anatomically connected regions (Braak and Braak, 1991; Braak et al., 2003) . This suggests the following sequence: a localized release of the deleterious protein assemblies at/around synapses, binding to the nearby synaptic plasma membrane, internalization in the adjacent neurons, and anterograde or retrograde transport with a possible amplification resulting from the recruitment and aggregation of endogenous soluble proteins. In case of trans-synaptic transfer, the distance to travel by means of 3D diffusion is small compared with that of the synaptic cleft, taking into account the space limitation by astroglia. Another but not exclusive possibility would be that pathogenic protein secretion/release and uptake would take place at a distance from synaptic sites that involve binding and uptake at adjacent or neighboring cell membranes. Anyhow, the propagations involve neuron-to-neuron and/or neuron-to-glial transfer (Pearce et al., 2015) . The next sections will focus on various biomolecules that may contribute to the binding of pathogenic proteins on the external surface of neurons and the biophysical consequences of these interactions. 
DIFFUSION
Dispersion from one region of space to another resulting from random movements of particles. Pathogenic proteins diffuse randomly in the 3D extracellular space (3D) and bind to the plasma membrane, where they diffuse in the 2D plane. During diffusion, they may bind to or unbind from various proteins/lipids.
SINGLE-PARTICLE TRACKING
Monitoring the movements of fluorescently labeled particles (e.g., proteins) at a single-molecule level, allowing the determination of characteristic physical properties. The diffusion behavior of single pathogenic proteins can be visualized using tagged assemblies. The label can make use of the biotin-streptavidin complex for quantum dot-based tracking, photo-convertible dyes (such as Dendra2 and mEos; Li et al., 2016) for super-resolution PALM-based tracking, or fluorescent antibodies (fragment antigen-binding [F ab ] or nanobodies) for universal point accumulation for imaging in nanoscale topography (uPAINT) (Chamma et al., 2016) .
DIFFUSION COEFFICIENT
The surface area explored per unit time by a diffusing particle. The diffusion coefficient (D) is a physical characteristic that will depend on the size of diffusing molecules, the physical properties of the surrounding environment, temperature, and pressure. In biological systems, it is an effective diffusion coefficient that depends on local viscosity and molecular interactions. This is why a broad range of diffusion coefficients (10 À4 -10 mm 2 /s) is observed for pathogenic proteins when diffusing on the plasma membrane. As expected, a larger protein complex (e.g., an aggregate) will diffuse slower than a smaller complex. The value of the diffusion coefficient is computed using mean square displacement values (MSD, see below).
MSD
MSD is defined as the square of the displacement of a particle at a given time relative to the position of the particle at zero time, averaged over many particles (Dix and Verkman, 2008) . The shape of the MSD versus time curve forms the basis of classification of different modes of diffusion, such as Brownian/normal or anomalous or directed diffusion ( Figure A) .
CHARACTERIZATION OF DIFFUSION BEHAVIOR BASED ON MSD
Normal or Brownian diffusion: The diffusion of particles in a homogeneous solution where the size of the diffusing particle is comparable with other molecules in the solution. The primary determinants of diffusion of a given particle are the particle size and shape. Because of local heterogeneities of biological systems, Brownian diffusion is only an approximation. For Brownian diffusion, MSD (r 2 ) follows a linear relation with time ( Figure A , blue trace). The MSD (r 2 ) of a particle is related to the dimension of diffusion (2D or 3D) by the following equations (Saxton and Jacobson, 1997) :
Anomalous diffusion: Biomolecules diffuse in a non-homogeneous environment, with particles (e.g., proteins) of various sizes and shapes present in the solution, within a volume or surface having heterogeneous properties ( Figure A, green trace) . On the plasma membrane, pathogenic proteins exhibit anomalous diffusion behavior. This is because pathogenic proteins encounter both resident membrane proteins/lipids and other pathogenic proteins with which they interact and/or collide. The inter-molecular collisions and interactions within the membrane prevent Brownian behavior. For anomalous diffusion, the MSD (r 2 ) of a particle is related to D by the following equations (Saxton and Jacobson, 1997) :
a is a measure of non-linearity. Typically, on the plasma membrane, a < 1, and the diffusing behavior is qualified as anomalous subdiffusion. Table 1 ). Although they do not have ''specific receptors'' and interact with many membrane-associated molecules and diverse protein assemblies, their distinct surface properties exhibit different affinities for molecules at the cell surface. They cluster on the plasma membrane of neuronal and non-neuronal cell types and trigger deleterious consequences resulting from protein assemblies that drive changes in lipid bilayer fluidity, membrane architecture, and the normal distribution of membranous proteins. Several plasma membrane and membrane-associated components (proteins, lipids, and ECM) affect and/or contribute to the interaction of Box 1. Continued
DIRECTED DIFFUSION
A particle follows directed motion; for example, when bound to cytoskeletal structures through molecular motors, it moves with a given velocity along one direction ( Figure A , red trace). It also diffuses over a short distance in the perpendicular direction because of the flexibility of the cytoskeletal element, or it diffuses isotropically over short distances from its attachment point because of the flexibility of the attachment (Saxton and Jacobson, 1997) . This type of diffusion is observed when a pathogenic protein is bound to vesicles following endocytosis and anterogradely/retrogradely trafficked along microtubules. The MSD (r 2 ) of a particle, for a velocity, V, is related to D by the following equation: Shown are trajectories of a pathogenic protein diffusing in 3D (green) or 2D (blue) space (left). The orange spot depicts the point of origin (for example, release site). In 3D and non-infinite time intervals, the probability for a random walk to never return to its starting point is certain (Ben-Naim et al., 2008) . In 2D, a randomly diffusing trajectory is certain to return to its starting point in a given time interval and depends mainly on the diffusion coefficient. The MSD versus time plot (right) for a pathogenic protein in the 3D extracellular space has the characteristic of anomalous diffusion because of heterogeneous viscosity of the extracellular space in which it travels. When interacting with the plasma membrane plane, the diffusion of the same protein will be restrained to a 2D space.
Here the anomalous diffusion displays increased confinement (blue curve, downward shift) resulting from the crowded environment (Saxton and Jacobson, 1997) . The reduction of the volume available for diffusion forms extracellular space (3D), so the cell surface (2D) increases the probability of molecular encounters at the plasma membrane, which, consequently, acts as a chemical reactor.
misfolded protein assemblies, whether naked or in complex with other secreted proteins (Table 1) .
Interactions with the ECM Components
Both the type and net charge of the ECM components and the size and net charge of the misfolded protein assemblies contribute to their binding and further aggregation. ECM components may act as a barrier restricting access to the plasma membrane: neurons with abundant ECM components are devoid of neurofibrillary tangles of tau in AD (Br€ uckner et al., 1999; H€ artig et al., 2001; Morawski et al., 2010) and are protected against Ab neurotoxicity (Miyata et al., 2007) . The implication of ECM components has been reinforced by recent studies using mice lacking aggrecan (chondroitin sulfate proteoglycan), cartilage link-protein 1 (stabilizing the interaction between hyaluronic acid and proteoglycans such as aggrecan), or tenascin-R (extracellular glycoprotein) (Suttkus et al., 2016) . Mouse knockout for any of the three components increased the internalization of tau protein and, consequently, increased tau spreading (Suttkus et al., 2016) . Other glycoproteins, such as reelin (secreted protein), were shown to protect neurons by binding soluble Ab species, thus delaying fibril formation and preventing spine loss (Pujadas et al., 2014) . In contrast, ECM components such as proteoglycans containing heparan sulfate side chains (HSPGs) promote the binding and internalization of misfolded protein assemblies, including PrP (Horonchik et al., 2005) , tau, and a-syn (Holmes et al., 2013) or Ab (Kanekiyo et al., 2011) . Although agrin and glypicans were identified in a proteomics screen with fibrillar a-syn assemblies (Shrivastava et al., 2015) , the implication of specific HSPGs remains unclear. Apart from contributing to Ab assemblies binding to cells, HSPGs also promote the conversion of non-fibrillar amyloid Ab into neurotoxic fibrillar forms in AD. HSPGs, including agrin and glypicans, are associated with senile plaques in the brain of human AD patients (Verbeek et al., 1999; van Horssen et al., 2002) . Agrin also binds to a-syn in a heparan sulfatedependent manner, induces conformational changes, and favors aggregation (Liu et al., 2005) . In the same line, agrin colocalizes with Lewy bodies in the substantia nigra in the PD brain (Liu et al., 2005) . Altogether, these data indicate that HSPGs not only contribute to the binding of misfolded protein assemblies but also promote their aggregation. It is plausible that, although agrin-HSPG promotes fibrillization, another unknown HSPG promotes internalization. A recent study showed that hyposialylation favors the cellular uptake of Ab (Bosch-Morató et al., 2016) . A clearer picture of the structure, function, and distribution of the ECM is still emerging, but, based on these studies, it appears that chondroitin-sulfated proteoglycans may safeguard neurons from pathogenic proteins, whereas heparansulfated proteoglycans increase neuronal vulnerability.
Interactions with Lipid Components
Direct interactions of misfolded protein assemblies with the outer lipid leaflet of the plasma membrane contribute to their binding to cells. For instance, Ab assemblies interact with cholesterol (Avdulov et al., 1997; Di Scala et al., 2014) and with gangliosides (Yanagisawa et al., 1995; Molander-Melin et al., 2005) , a class of amphiphilic glycolipids at the external membrane leaflet exposing oligosaccharide chains toward the exterior of the cell. Further aggregation of Ab assemblies occurs on interaction with cholesterol (Avdulov et al., 1997) and the ganglioside GM1 (Hong et al., 2014) . In the same line, a-syn assemblies interact with negatively charged phospholipids (Pieri et al., 2012) , cholesterol, and gangliosides Yahi, 2011, 2013; on the outer leaflet of the plasma membrane. The binding of a-syn assemblies to lipids is further supported by single-particle tracking on the neuron surface showing high diffusion speed and long trajectories (Shrivastava et al., 2013) with features similar to those of lipids (Renner et. al., 2009) prior to their clustering. Similarly, tau protein and huntingtin interact with phospholipids (Jones et al., 2012; Patel et al., 2015; Pieri et al., 2012; Burke et al., 2013) , and huntingtin was also found to be associated with lipid raft-enriched, detergentresistant membranes (Valencia et al., 2010) . Interactions with Membrane Proteins Direct interaction of misfolded protein assemblies with membrane proteins has received significant attention since pharmacological and genetic tools allow manipulation of such interactions. Membranous PrP c (cellular prion protein) interacts with aggregated PrP; e.g., PrP RES (Aguzzi and Falsig, 2012) .
A recent study identified PrP c as a ligand for the G proteincoupled receptor Gpr126 in Schwann cells (K€ uffer et al., 2016) . Although Gpr126 is not expressed in neurons, this study indicates that neuronal PrP RES may not only bind to PrP c but also acts as a ligand for other neuronal G protein-coupled receptors such as mGluR5s, which physically interact with PrP c (Um et al., 2013) . Several membrane proteins (Table 1) have been shown to interact with Ab assemblies (Jarosz-Griffiths et al., 2016) . Just to mention some of these interactions, Ab assemblies bind with high affinity to a7-nicotinic acetylcholine receptors (Wang et al., 2000; Dineley et al., 2001; Snyder et al., 2005; Dziewczapolski et al., 2009) , leukocyte immunoglobulin-like receptor B2 (Kim et al., 2013) , a3-Na (Ohnishi et al., 2015) , Ephrin B2 receptor (EphB2) (Cissé et al., 2011a) , and the PrP c -mGluR5 complex (Lauré n et al., 2009; Renner et al., 2010; Um et al., 2013; Haas et al., 2014 Haas et al., , 2016 Hu et al., 2014) . Among these, because of available pharmacological agents, Ab interaction with PrP c -mGluR5 has received much attention. Although PrP c knockout does not abolish Ab binding (2), receptors and channels (3), and ECM components, including glycoproteins (4) or carbohydrate chains (5). Also see Table 1 for known pathogenic protein binding partners.
to cells and subsequent neurotoxicity (Balducci et al., 2010; Calella et al., 2010; Kessels et al., 2010; Cissé et al., 2011b) , knocking down mGluR5s (Hamilton et al., 2014) and pharmaceutical inhibition of mGluR5s (Um et al., 2013; Hamilton et al., 2016) delay neurodegeneration significantly. This suggests that mGluR5s is the critical membranous partner for Ab pathologic (Caughey et al., 1994) HSPGs (Fraser et al., 1992) HSPGs (Cohlberg et al., 2002) HSPGs (Goedert et al., 1996) Glypican-1 (Taylor et al., 2009) Perlecans (Castillo et al., 1997) Agrin (Liu et al., 2005) Glypican-1 (Watanabe et al., 2004) Agrin (Cotman et al., 2000) Reelin (Pujadas et al., 2014) Lipids cholesterol (Avdulov et al., 1997) cholesterol ganglioside GM1 (Yanagisawa et al., 1995) ganglioside GM1 (Martinez et al., 2007) ganglioside GM3 (Di Pasquale et al., 2010) Membrane proteins PrP c (Brandner et al., 1996) RAGE (Yan et al., 1996) a3-Na AMPA receptors (Zhao et al., 2010) mGluR5 (Renner et al., 2010) b2-adrenergic receptor (Wang et al., 2010) EphB2 (Cissé et al., 2011a) Neuroligin 1 (Dinamarca et al., 2011) Amylin-3 receptor (Fu et al., 2012) FcgRIIb (Kam et al., 2013) PirB/LilrB2 (Kim et al., 2013) EphA4 (Vargas et al., 2014) Sigma-2/PGRMC1 receptors (Izzo et al., 2014) a3-Na + /K + -ATPase (Ohnishi et al., 2015) Neurexin subunits 2a (Brito-Moreira et al., 2017) 1b/2b/3b (Naito et al., 2017) Adgrg6, adhesion G protein-coupled receptor G6 or GPR126; a3-Na + /K+-ATPase, a3 subunit of sodium potassium ATPase; AMPA, a-amino-3- assemblies. Co-localization of Ab oligomers and mGluR5s were also observed on astrocytes in mice and humans (Casley et al., 2009; Lim et al., 2013; Shrivastava et al., 2013) .
A comparable mechanism was found for a-syn assemblies, which interact with the neuron-specific a3 subunit of the sodium pump NKA (Shrivastava et al., 2015) . Another study showed that binding of a-syn fibrils to membrane protein lymphocyte activation gene 3 (LAG3) contributes to a-syn endocytosis and cell-tocell transmission and toxicity (Mao et al., 2016) . Assemblies of a-syn also bind to other membrane proteins; e.g., neurexin subunits (Shrivastava et al., 2015; Mao et al., 2016) , amyloid b precursor-like protein 1 (Mao et al., 2016) , and the glucose-related protein of 78 kDa (GRP78; Bellani et al., 2014) . Finally, extracellular tau assembly interaction with muscarinic receptors has been reported (Gó mez- Ramos et al., 2008) .
Thus, misfolded protein assemblies may interact with ECM components (HSPGs and glycoproteins), outer membrane lipids (cholesterol and gangliosides), and membranous proteins (Table 1 ). This diversity of partners suggests that there is no specific ''receptor'' for misfolded protein assemblies. The availability of multiple binders within the plane of the plasma membrane suggests that these multiple interactions increase pathogenic protein density, thus promoting 2D diffusion-dependent inter-molecular interactions inducing clustering and subsequent toxicity.
Consequences of Pathogenic Protein Binding to the Cell Membrane Single-particle tracking and high-resolution imaging approaches have shed new light on the fate of misfolded protein assemblies after binding to the plasma membrane. The clustering of pathogenic proteins on the plane of the membrane results in the redistribution and trapping of membrane proteins and lipid molecules by a so-called diffusion trap mechanism comparable with that described for the interaction between receptors and scaffolding proteins and their subsequent accumulation at synapses (Triller and Choquet, 2008) .
Changes in the Biophysical Properties of Pathogenic Proteins
In a manner similar to native functional proteins, misfolded proteins oscillate between different shapes, exposing diverse amino acid residues and surfaces (Fersht, 1999) . This allows longitudinal and/or lateral interactions between like molecules, leading to fibril formation (Eisenberg and Jucker, 2012; Brundin et al., 2010) . Metastable pre-fibrillar oligomeric precursors form in the early stages of assembly into fibrils (Goldberg and Lansbury, 2000; Lashuel et al., 2002) . To date, an extremely large variety of oligomeric species that differ in structure, molecular weight, and morphology have been described (Danzer et al., 2007; Cremades et al., 2012; Qin et al., 2007; Ehrnhoefer et al., 2008; Zhou et al., 2010; Pieri et al., 2016) . In addition, the distinct conformation a pathogenic protein may adopt through its ''chameleon'' property in solution (Uversky, 2003) allows interactions with membrane components with different affinities. The interaction of misfolded proteins and their assemblies with membrane components restricts the conformational states they explore in solution (Onuchic et al., 1996) . This is achieved by displacing the equilibrium between the different conformations they may adopt toward the one with the highest affinity for membrane components. Thus, for any given protein involved in neurodegenerative diseases, binding to membrane components selects specific conformations of the many they can adopt. In addition, the diffusion-dependent interaction of misfolded proteins and their assemblies with membranous components increases their local concentration. This is due to the shift from 3D to 2D diffusion. The subsequent molecular crowding increases the probability to reach a critical concentration, above which thermodynamically stable misfolded protein assemblies form and further grow in an unlimited manner (Oosawa and Asakura, 1975) . Distinct membrane component-mediated selection of different protein conformers/oligomers together with the diffusion-dependent increase in protein conformer/oligomer concentration may be at the origin of the aggregation of a given protein into strains; e.g., structurally and functionally distinct assemblies. Overall, the plasma membrane sorts misfolded assemblies in a way that may favor selected pathogenic conformations and promote molecular clustering/aggregation (Box 2).
Lateral Diffusion and Aggregation of Pathogenic Proteins
Whether interacting with membrane-bound ECMs, lipid molecules, or membranous proteins, misfolded proteins and their assemblies exhibit anomalous diffusion along the plane of the membrane (Renner et al., 2010; Shrivastava et al., 2013 Shrivastava et al., , 2015 . While diffusing, misfolded protein molecules and/or their assemblies may encounter identical molecules, resulting Proteins in general and natively unfolded polypeptides in particular adopt numerous conformations. Let us assume that each amino acid residue can adopt three conformations (one trans and two gauche) with two torsion angles within a natively unfolded polypeptide made of 100 amino acid residues. The number of conformations such a polypeptides could adopt would be 3 99x2 ; i.e., 10 95 possible conformations. The concentration and lifespan of each conformer are characteristic of the precise conformation the polypeptide adopts. The amino acid stretches exposed at the surface of a given conformer define its association and dissociation constants with different membrane components. The reversible binding of defined conformers with cell membrane components favors those conformations by displacement of the equilibria between the different conformers in solution toward those that bind with the highest affinity to membrane components. Thus, membrane components operate a triage between numerous conformers. When aggregation-prone conformations are populated by specific selection through binding to membrane components, further binding may either be negative (when the binding of one molecule opposes the binding of others) or positive (when the binding of one molecule facilitates the binding of others). Unless binding is negative, the local concentration of aggregation-prone conformers increases, favoring cooperative aggregation.
in interaction-driven aggregation, which, in turn, may induce abnormal or pathogenic distribution of partner membranous components (discussed below in Trapping and Clustering of Membrane Proteins). Thus, by restricting the space of diffusion from 3D to 2D, the plasma membrane acts as a chemical reactor (Figure 2 ; Salvatico et al., 2015) , favoring molecular interactions. A good example is that of Ab oligomers, the aggregation of which increases on 2D charged membranes with the amount of charged lipids, consequently forming toxic aggregates because of molecular crowding (Bokvist et al., 2004; Bokvist and Grö bner, 2007) . A recent study highlights the biological relation of membrane aggregation to toxicity for Ab assemblies using mouse models where Ab was either membrane-anchored or nonanchored (Nagarathinam et al., 2013) . Membrane-anchored but not non-anchored Ab-accelerated Ab deposition exacerbated amyloid-associated toxicity upon crossing with Ab precursor protein transgenic mice (Nagarathinam et al., 2013) . This study established that chronic association of Ab peptides with the plasma membrane accelerates neurodegeneration. This is in line with work suggesting that the plasma membrane is the initial site for plaque deposition in human AD patients (Yamaguchi et al., 2000) as well as in a rodent model (Kokubo et al., 2005) .
In the case of a-syn, the oligomeric form shifts from a mono-to poly-dispersed structures in the presence of phospholipid membranes (Anunciado et al., 2015) . Accordingly, the clustering of a-syn assemblies on the neuronal plasma membrane has been shown with super-resolution microscopy (Shrivastava et al., 2015) . Using electron microscopy, another study reported that plasma membrane-bound fibrils of a-syn serve as nucleation sites for the aggregation and conversion into amyloid-like structures for extracellular monomeric a-syn (Mahul-Mellier et al., 2015) . In the case of PrP RES conversion, replication, and aggregation, the role of membranes has also been established. The lipid-rich domains on the plasma membrane are the sites for PrP RES aggregation and rapid conversion (Goold et al., 2011; Godsave et al., 2013; Rouvinski et al., 2014) . Furthermore, in vivo studies identified plasma membrane invaginations with PrP RES aggregates as an early sign of prion disease (Godsave et al., 2013) . In addition, PrP RES remained on the cell surface for hours, in the form of slow-moving strings and webs, sheltered from endocytosis (Rouvinski et al., 2014) .
Pore Formation
The crowding at the plasma membrane rises with the increasing concentration of misfolded protein assemblies. This, together with the clustering and further aggregation of misfolded protein assemblies into higher-order structures ranging from pore-like to raft-like structures (Danzer et al., 2007; Kayed et al., 2003 Kayed et al., , 2004 Kostka et al., 2008) , has consequences on overall membrane overall integrity, physical properties, and geometry (Antonny 2011; Garten et al., 2015; Milanesi et al., 2012; Li and Gorfe, 2014) .
Trapping and Clustering of Membrane Proteins
Following their diffusion, both Ab and a-syn assemblies form clusters in the vicinity of synapses (Renner et al., 2010; Shrivastava et al., 2015) . The preferential clustering of misfolded protein assemblies around curved membranous structures such as synapses could be either due to their higher affinity for defined membrane geometry (Pranke et al., 2011) or due to protein partners within these structures. In any case, the clustering of misfolded proteins affects the dynamic properties of both their membranous partners and the membrane geometry. The reduced dynamics and/or trapping of misfolded proteins partners, ECM, and lipids leads to aberrant, non-physiological distribution and, eventually, pathological gain or loss of signaling functions (Figure 2 ; Calamai and Pavone, 2013; Calamai et al., 2016; Ganzinger et al., 2014; Hong et al., 2014; Ross and Poirier, 2004; Renner et al., 2010; Shrivastava et al., 2013 Shrivastava et al., , 2015 Yu et al., 2014) . The increased localization of mGluR5s following diffusion trapping by Ab assemblies at excitatory synapses and, more specifically, at dendritic spines (Figure 3 ) results in a constitutively activated signaling platform (gain of function) characterized by an increased mGluR5s-dependent Ca 2+ response (Renner et al., 2010) . The increased Ca 2+ response is either the consequence of Ab assemblies directly activating mGluR5s or PrP C -mediated activation of mGluR5s (Um et al., 2013; Haas et al., 2014 Haas et al., , 2016 Hu et al., 2014) . The non-physiological misfolded Following binding to the plasma membrane, pathogenic proteins diffuse along the 2D plane that will favor interaction (also see Box 1) with other proteins (other pathogenic proteins and membrane receptors; Table 1 ). Left: interactions between pathogenic proteins promote their aggregation, often observed in the vicinity of synapses. Right: the aggregates of pathogenic proteins will trap diffusing native membrane components, resulting in the formation of clusters. Thus, the presence of non-physiological aggregates of pathogenic proteins can alter the distribution and function of physiologically important membrane proteins such as receptors, channels, or pumps (from left to right).
protein-mediated redistribution of partners within the membrane can also mimic the loss of function of a signaling pathway, observed following Ab-and a-syn-mediated re-distribution of the a3-NKA (Figure 3 ; Ohnishi et al., 2015; Shrivastava et al., 2015) . Similarly, Ab assembly-mediated GM1 clustering (Calamai and Pavone, 2013; Hong et al., 2014) will affect the maintenance of raft-like domains and membrane viscosity (Eggeling et al., 2009; Renner et al., 2009) . Changes in the Topography of the Plasma Membrane Misfolded protein binding, lateral diffusion, and further aggregation within the plasma membrane and misfolded protein-mediated redistribution of membranous partner molecules remodel the topography and fluidity of the plasma membrane. The changes range from alteration in membrane outer leaflet lipid composition because of the extraction of lipids from the lipid bilayer (Pandey et al., 2009; van Rooijen et al., 2009; Reynolds et al., 2011; Hellstrand et al., 2013) to the stiffening of the plasma Following their binding and clustering in the vicinity of synapses, pathogenic proteins initiate deleterious effects by forming artificial signaling platforms. This can be a loss-of-function platform (e.g., a-syn/a3-NKA; Shrivastava et al., 2015) or gain-offunction platform (e.g., the Ab/mGluR5 complex; Renner et al., 2010) . These platforms alter the ionic gradient in neurons by compromising the activity of trapped membrane proteins. The functional coupling of a3-NKA/mGluR5s with NMDA receptors indirectly alters the activity of the latter, resulting in Ca 2+ -dependent toxicity.
membrane to the point where its integrity is compromised following rupture (Varkey et al., 2010; Pieri et al., 2012) Alterations in Synaptic Scaffold Composition Membrane receptors are stabilized at synapses by their interaction with submembranous scaffold proteins. A synapse can be described as a three-layer structure: a membrane, a sub-membrane, and a bulk layer (Sekimoto and Triller, 2009 ). This layered organization at the postsynaptic region is maintained through reciprocal interactions where scaffold proteins stabilize synaptic receptors that, in turn, stabilize scaffold proteins (Sekimoto and Triller, 2009) . A similar mutual stabilization process may occur when pathogenic assemblies interact with partner molecules. Such interactions may subsequently lead to alteration of the sub-membrane proteins and their interacting partners' organization. A recent example of such a mechanism is that of PTEN (phosphatase and tensin homolog)-altered accumulation in spine heads following exposure to Ab assemblies (Knafo et al., 2016) . The recruitment of PTEN is likely to result from an increased association of PTEN with PSD-95 via a PDZ domaindependent interaction (Knafo et al., 2016) . Although speculative, the underlying mechanism may involve a liquid-liquid phase separation mechanism, which has been recently proposed in an unrelated study (Zeng et al., 2016) Physiological Changes because of Misfolded Protein Assembly-Mediated Clustering of Partner Proteins Glutamate Receptors Activation Excessive influx of Ca 2+ disrupts ion homeostasis, cell metabolism, and initiates the activation of apoptotic and necrotic pathways. Indeed, the intracellular Ca 2+ ([Ca 2+ ] i ) level regulates the number and composition of receptors/channels in and outside of synapses (Choquet and Triller, 2013) . Thus, the clustering of pathogenic proteins and membrane receptors around the excitatory synapses will affect glutamate receptor signaling by constraining the flux of glutamate receptors in and out of synapses. In addition, functional coupling of glutamate receptors, specifically N-methyl-D-aspartate (NMDA) receptors with several synaptic receptors, such as mGlu5Rs (Rammes et al., 2011) , a3-NKA (Akkuratov et al., 2015) , EphB (Nolt et al., 2011; Cissé et al., 2011a) , etc., could impair NMDA receptor function and, consequently, long-term potentiation in neurodegenerative diseases (Shankar et al., 2007; De Felice et al., 2007; Cissé et al., 2011a; Li et al., 2011; Rammes et al., 2011; Dió genes et al., 2012; Hu et al., 2014) .
The metabotropic glutamate receptors, specifically mGluR5s, also contribute to a rise in [Ca 2+ ] i , which can be deleterious for neurons. The exposure of neurons to Ab oligomers induces mGluR5-dependent release of Ca 2+ from the endoplasmic reticulum and, consequently, toxicity (Renner et al., 2010; Um et al., 2013) . Similarly, in astrocytes, Ab oligomers cluster mGluR5, leading to an increase in [Ca 2+ ] i (Lim et al., 2013; Shrivastava et al., 2013) . Thus, the mGluR5 platforms resulting from clustering lead to a gain of function and contribute to the deleterious effects of Ab oligomers. In PD, mGluR5 antagonists are neuroprotective, but their mechanism of action remains unclear (Morin et al., 2013) . Co-localization and co-immunoprecipitation of mGluR5s with a-syn has been reported in the hippocampus (Price et al., 2010; Overk et al., 2014) . Furthermore, increased expression of mGluR5s has been reported in PD patient brains (Sanchez-Pernaute et al., 2008; Price et al., 2010) . Notably, an upregulation of mGluR5s has been observed not only in PD and AD but several other neurodegenerative disorders. The upregulation, increased clustering, and increased surface expression of mGluR5 in neurons and astrocytes could be part of a neuroinflammatory response dependent on extracellular ATP/ adenosine concentration (Pascual et al., 2012; Shrivastava et al., 2013) , but this needs further evaluation. In any case, the increased surface availability of mGluR5s and its deleterious clustering is likely at the origin of elevated [Ca 2+ ] i . High [Ca 2+ ] i will trigger calpain activation, endoplasmic reticulum stress, increased autophagy, and cell death (Figure 3 ; Mattson, 2007) . Impairment of Ion Transporters Both Ab (Ohnishi et al., 2015) and a-syn (Shrivastava et al., 2015) interact with the a3 subunit of the NKA and impair the function of this pump. Remarkably, both Ab and a-syn were found to bind to the same amino acid stretch centered on asparagine ( Asn 879 ) that is located in the third extracellular loop of the a3 subunit of NKA. The binding of Ab oligomers to a3-NKA was reported to impair its catalytic activity, measured as ATP hydrolysis (Ohnishi et al., 2015) . The binding of a-syn to a3-NKA was reported to decrease the capacity of the transporter to rapidly extrude sodium ions because of aberrant co-clustering around synapses. Both interactions were found to increase Ca 2+ excitotoxicity (Figure 3) .
NKA restores the intracellular ion imbalance following action potential propagation by transporting three Na + out of and two K + into the cell at the expense of one molecule of ATP. The minimal functional unit of NKA is a dimer, consisting of a catalytic a subunit and a b subunit; the latter is required for the insertion of NKA into the membrane (Kaplan, 2002) . Neurons express two isoforms of the catalytic a subunit: the ubiquitous a1 and the neuron-specific a3. The neuron-specific isoform has a lower affinity for Na + than the ubiquitous a1 isoform and is in a better position to take care of large transient increases in intracellular Na + during high neuronal activity (Azarias et al., 2013) . The a3 subunit also plays a pivotal role in the dynamic control of membrane potential. The brain is dependent on a functional NKA a3 subunit. Mutations in the a3 subunit have been described in several rare diseases (Heinzen et al., 2014) with severe neurological disturbances, and recently it has been reported (Ruegsegger et al., 2016) that the intracellular interaction between the a3 subunit and the ALS-associated human mutant of SuperOxide Dismutase (SOD) accounts for some of the ALS symptoms. Furthermore, in the healthy brain, NKA activity accounts for approximately 50% of total brain energy consumption (Harris et al., 2012) . Mitochondrial dysfunction is a common feature in genetic and sporadic PD, and mitochondrial dysfunction has also been shown to play an important role in the pathophysiology of AD (Johri and Beal, 2012) . Based on the recent findings that a-syn and Ab assembly binding to the extracellular domain of the neuronal a3 isoform of NKA is deleterious, one can speculate that these neurodegenerative diseases are associated with a brain energy crisis where both the supplier and the processor of the energy are at stake.
Therapeutic Perspectives
The prion-like effects of Ab, a-syn, and other pathogenic proteins offer alternative therapeutic strategies. Targeting extracellular and/or membrane-bound pathogenic assemblies and/or their interaction partners could prevent some of the early deleterious steps that lead, with time, to neurodegeneration. A first approach based on the inhibition and/or reduction of pathogenic protein assembly binding to the membrane should diminish their ability to further assemble and reorganize into toxic macromolecular structures. It could also prevent alterations in membrane components' dynamics and clustering. A second approach relying on the pharmacological modulation of the activity of plasma membrane proteins interacting with pathogenic assemblies would provide an additional therapeutic tool that would provide rescue from the downstream effects of deleterious signaling. Disrupting Pathogenic Protein Binding to the Plasma Membrane The clustering of pathogenic proteins and their assemblies within the cell membrane can indeed generate protein scaffolds that actively recruit other neuronal membrane proteins and compromise their function or normal distribution. Alternatively, the binding and docking of pathogenic protein assemblies may affect the overall normal distribution of membrane proteins through a passive exclusion mechanism, leading to a pathologic distribution. Understanding these changes is a prerequisite for a therapeutic strategy aimed at restoring the normal protein distributions. Recent studies have demonstrated that the binding of ligands (such as hsc70) to pathogenic protein assemblies can affect their ability to interact with the plasma membrane components, resulting in decreased toxicity (Pemberton et al., 2011) . One cannot fully prevent the binding of pathogenic assemblies to the neuronal membrane. However, reducing the concentration of unbound assemblies within the extracellular milieu is eventually doable by the use of antibody-based therapies. Antibodies targeting Ab are neuroprotective in rodent models (Busche et al., 2015; Bales et al., 2016; Wisniewski and Goñ i, 2015) . Preliminary studies suggest that they may be beneficial to humans (Sevigny et al., 2016) . Similarly, antibodies directed against tau blocked the pathogenic protein aggregates outside of the cells, in the inter-cellular space (Kfoury et al., 2012; Yanamandra et al., 2013 Pedersen and Sigurdsson, 2015; Castillo-Carranza et al., 2015) . Immunization also prevented pathogenic a-syn from interacting with cells (Mandler et al., 2014 (Mandler et al., , 2015 Tran et al., 2014 ). The precise mechanisms of antibody-mediated clearance of misfolded assemblies are unclear, and it is believed that microglia play a critical role in the clearance of antibody-bound assemblies. Other clearance mechanisms may include blockade of neuronal uptake (Funk et al., 2015) by therapeutic antibodies. Antibodies targeting extracellular pathogenic protein aggregates only recently showed some effectiveness in patients with AD and other neurodegenerative diseases (Ising et al., 2015; Sevigny et al., 2016) . The shortcomings of this and other clinical trials is that they were mostly initiated late in the course of the disease, when neurodegenerative symptoms are well established. The development of amyloid imaging methods in AD and novel biomarkers should help to resolve this problem in the future and allow the studies to be carried out earlier. Currently, there are several ongoing pre-clinical and clinical studies validating the therapeutic potential of antibodies targeting Ab (Ising et al., 2015; Sevigny et al., 2016) , tau (Pedersen and Sigurdsson, 2015) , and a-syn (Bergströ m et al., 2016) . Counteracting Pathogenic Protein Assembly-Mediated Membrane Protein Redistribution The clustering of membrane proteins following the binding of pathogenic assemblies results in a gain of function or loss of function as described above (Figure 3) . Strategies relying on identification of the surface interfaces between pathogenic protein assemblies and their membranous partners possess therapeutic potential. The a3-NKA site that interacts with Ab assemblies was identified based on molecular modeling (Ohnishi et al., 2015) . Small peptides reproducing this interface prevented Ab assemblies from interacting with a3-NKA and were shown to be neuroprotective in a preliminary in vitro study (Ohnishi et al., 2015) . Similarly, small peptides preventing Ab binding to EphB2 rescued the impaired synaptic plasticity and memory deficits in a mouse model of AD by modulating NMDA receptors . This suggests that the peptides may have acted as a decoy to lure Ab aggregates away from interacting membrane receptors and emphasizes the therapeutic potential of targeting specific interfaces between pathogenic protein aggregates and their membrane protein partners.
New knowledge about the deleterious interactions between Ab, a-syn, and tau on one hand and plasma membrane proteins on the other hand will make it possible to develop antibodies with epitopes targeting the interaction domain on plasma membrane proteins. Such protective antibodies have been developed in CJD and proved to be therapeutically efficient in animal studies. The protective antibodies, which bind to the non-structured octapeptide domain of PrP c , alter their conformations in a way that counteracts the toxicity of misfolded prions (Sonati et al., 2013; Herrmann et al., 2015) . In another study, it was shown that antibodies binding to a specific segment on PrP c decreased their interaction with mGluR5s, a modulator of neurodegeneration in AD (Haas et al., 2014) . Thus, immunotherapy targeting membrane partners of pathogenic proteins could offer neuroprotection. Pharmacological modulation of the plasma membrane proteins that interact with pathogenic proteins is a simpler approach to developing a symptomatic therapy. Several receptors associated with Ca 2+ signaling have been implicated in the pathophysiology of neurodegenerative disorders, especially AD (Table 1) . A causal relationship between Ab aggregation and mGluR5 dysfunction has also been established, and two different antagonists of mGluR5s reversed memory deficit in AD mouse models (Um et al., 2013; Hamilton et al., 2016) . Among other Ab-interacting membrane proteins, nicotinic acetylcholine receptors agonists/antagonists (Lombardo and Maskos, 2015) and the EphB2 inhibitors (Fu et al., 2014) are promising targets for AD. Several studies have demonstrated hyper-excitability in NMDA receptors in experimental models of AD, and there are clinical trials with moderately inhibitory NMDA receptor antagonists (Howard et al., 2012) .
Shielding the membrane target of extracellular Ab and a-syn is emerging as a novel therapeutic strategy in both AD and PD. Given the number of pathogenic protein assembly partners at the surface of neurons (Table 1) , the use of agonists, inhibitors, or inhibitory peptides/antibodies targeting each partner protein may not be a therapeutic strategy that is easy to implement. An alternative strategy may involve the activation of pathogenic protein partners downstream of the signal transduction pathway. Indeed, a-NKA signaling, for instance, results in cell and tissue protection (Aperia et al., 2016) . However, this necessitates the development of novel modulators of neuronal pathogenic protein partners that counteract their redistribution upon exposure of neurons to pathogenic protein assemblies involved in AD and PD and compensate for their inactivation following their clustering; for example, by inducing their expression and/or restoring or mimicking their normal function and/or signaling activities. Thus, interfering with pathologic misfolded protein interaction with cell membranes by changing their surface properties in a way so that they are not capable of binding membrane-associated partner proteins and/or shielding their receptors will represent a novel avenue to halt or slow down the progression of AD, PD, and many other neurodegenerative diseases.
Limitations and Future Perspectives
Although cell-to-cell transmission of pathogenic protein assemblies has been demonstrated, the contribution of this process to disease is questioned. This is due to the experimental setups that have been used and due to atypical PD and AD cases, representing up to 15%-20% of the cases that exhibit pathogenic patterns dissimilar from those reported by Braak and coworkers (Braak and Braak, 1991; Braak et al., 2003) . Indeed, most of the experimental setups used so far are imperfect. High concentrations of pathogenic assemblies ranging from micromolar to nanomolar have been used to allow detection of the pathogenic assemblies. In addition, to favor amplification, transgenic animals, either overexpressing proteins which aggregation is involved in disease or variants of these proteins associated with familial forms of diseases with early onset, have been employed in most studies. These limitations can be surpassed by the use and development of highly sensitive, dynamic imaging tools such as structured illumination microscopy (Hong et al., 2016) , photo-activated localization microscopy (PALM)/STORM (stochastic optical reconstruction microscopy) imaging (Sigal et al., 2015) , tissue clearing (Liebmann et al., 2016) , and expansion approaches (Chen et al., 2015) . The use of mature neurons with well-developed synapses/spines, human-derived neuronal cells, and new animal models better suited to document human age-related disorders should also be developed. Despite the limitations listed above, the finding that fibrillar assemblies with distinct surfaces and structures yield different pathologies in animal models Peelaerts et al., 2015) strongly suggests that the interaction of divergent pathogenic assemblies with membranous partners and the redistribution of membrane protein partners they trigger specifically is critical for understanding neurodegenerative diseases progression. This is why it is mandatory to assess, at the highest possible resolution, the consequences of distinct pathogenic protein assembly binding to neuronal cell membranes to better understand the molecular processes leading to disease. Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C., and Aguzzi, A. (1996) . Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339-343.
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